In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Abbott acquires TheraSense for $1.12bn

Executive Summary

Abbott Laboratories is acquiring all the outstanding stock of blood glucose monitoring device company TheraSense for $27 per share (a 34% premium to the market average), valuing the deal at about $1.12bn.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Includes Contract
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register